martes, 9 de diciembre de 2014

National Guideline Clearinghouse | Practice parameter for the assessment and treatment of children and adolescents with schizophrenia.

full-text ►

National Guideline Clearinghouse | Practice parameter for the assessment and treatment of children and adolescents with schizophrenia.

American Academy of Child and Adolescent Psychiatry

Guideline Title

Practice parameter for the assessment and treatment of children and adolescents with schizophrenia.

Bibliographic Source(s)

McClellan J, Stock S, American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 2013 Sep;52(9):976-90. [130 references] PubMed External Web Site Policy

Guideline Status

This is the current release of the guideline.

This guideline updates a previous version: American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. Washington (DC): American Academy of Child and Adolescent Psychiatry; 2000 Jun 6. 40 p. [125 references]

---

Practice parameter for the assessment and treatment of children and... - PubMed - NCBI

2013 Sep;52(9):976-90. doi: 10.1016/j.jaac.2013.02.008.

Practice parameter for the assessment and treatment of children and adolescents with schizophrenia.

McClellan J, Stock S; American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI).

Abstract

This Practice Parameter reviews the literature on the assessment and treatment of children and adolescents with schizophrenia. Early-onset schizophrenia is diagnosed using the same criteria as in adults and appears to be continuous with the adult form of the disorder. Clinical standards suggest that effective treatment includes antipsychotic medications combined with psychoeducational, psychotherapeutic, and educational interventions. Since this Practice Parameter was last published in 2001, several controlled trials of atypical antipsychotic agents for early-onset schizophrenia have been conducted. However, studies suggest that many youth with early-onset schizophrenia do not respond adequately to available agents and are vulnerable to adverse events, particularly metabolic side effects. Further research is needed to develop more effective and safer treatments.